4-methyl-2-(4-nitrophenyl)-1,3-thiazole-5-carboxylic acid | 15911-30-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methyl-2-(4-nitrophenyl)-1,3-thiazole-5-carboxylic acid
• 英文别名: 4-methyl-2-(4-nitro-phenyl)-thiazole-5-carboxylic acid；4-methyl-2-(4-nitrophenyl)-5-thiazolecarboxylic acid
• CAS: 15911-30-5
• 化学式: C₁₁H₈N₂O₄S
• mdl: MFCD01936221
• 分子量: 264.262
• InChiKey: IAWXKDQKIJAATO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  124
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-methyl-2-(4-nitrophenyl)-1,3-thiazole-5-carboxylic acid 在 溴 作用下， 以 溶剂黄146 为溶剂， 生成 5-bromo-4-methyl-2-(4-nitro-phenyl)-thiazole
  参考文献：
  名称：

  对一些杂环研究的贡献，XLII。2-芳基-4-R-5-羧基-噻唑系列中羧基被溴取代

  摘要：

  研究了 2-芳基-4-R-5-羧基噻唑对溴和次溴酸的行为。

  DOI：

  10.1002/ardp.19763090207
• 作为产物：
  描述：

  4-甲基-2-苯基-1,3-噻唑-5-甲酸乙酯 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 生成 4-methyl-2-(4-nitrophenyl)-1,3-thiazole-5-carboxylic acid
  参考文献：
  名称：

  Csavassy,G.; Gyoerfi,Z.A., Justus Liebigs Annalen der Chemie, 1974, p. 1195 - 1205

  摘要：

  DOI：

文献信息

• 2-arylthiazole derivatives and pharmaceutical composition thereof
  申请人：Teijin Limited

  公开号：US05614520A1

  公开（公告）日：1997-03-25

  Pharmaceutical compositions for treating gout or hyperuricemia and containing a new categorized compound, i.e. 2-arylthiazole derivatives, as an active ingredient, are provided. The 2-arylthiazole derivatives in the present invention are represented by the following formula (I): ##STR1## wherein Ar is an unsubstituted or substituted pyridyl, thienyl, furyl, naphthyl or phenyl group; X is a hydrogen atom, alkyl group or carboxyl group which may be protected, and Y is a hydrogen atom, alkyl group, or a hydroxyl or carbonyl group which may be protected. Furthermore, novel compounds included in the 2-arylthiazole derivatives and pharmaceutically acceptable salts thereof are provided.

  提供用于治疗痛风或高尿酸血症的药物组合物，含有一种新分类化合物，即2-芳基噻唑衍生物，作为活性成分。本发明中的2-芳基噻唑衍生物由以下式（I）表示：其中Ar是未取代或取代的吡啶基、噻吩基、呋喃基、萘基或苯基；X是氢原子、烷基或可保护的羧基，Y是氢原子、烷基或可保护的羟基或羰基。此外，提供了包括在2-芳基噻唑衍生物中的新化合物及其药用盐。
• Discovery of cyclic amine-substituted benzoic acids as PPARα agonists
  作者：Masahiro Nomura、Kazuhiro Yumoto、Takehiro Shinozaki、Shigeki Isogai、Yasuo Takano、Koji Murakami

  DOI：10.1016/j.bmcl.2011.11.002

  日期：2012.1

  A series of novel cyclic amine-substituted benzoic acid derivatives were synthesized and evaluated for their PPAR alpha agonist activity. Strucure-activity relationship studies led to the identification of (S)-3-[3[2-(4-chlorophenyl)-4-methylthyazole-5-carboxamido] piperidin-1-yl] benzoic acid (S)-4f (KRP-105) as a potent and high subtype-selective human PPARa agonist. (S)-4f showed excellent PK profile and oral administration of (S)-4f to high-fat diet dogs effectively lowered triglycerides. (C) 2011 Elsevier Ltd. All rights reserved.
• Substituted 2-[(4-Aminomethyl)phenoxy]-2-methylpropionic Acid PPARα Agonists. 1. Discovery of a Novel Series of Potent HDLc Raising Agents
  作者：Michael L. Sierra、Véronique Beneton、Anne-Bénédict Boullay、Thierry Boyer、Andrew G. Brewster、Frédéric Donche、Marie-Claire Forest、Marie-Hélène Fouchet、Françoise J. Gellibert、Didier A. Grillot、Millard H. Lambert、Alain Laroze、Christelle Le Grumelec、Jean Michel Linget、Valerie G. Montana、Van-Loc Nguyen、Edwige Nicodème、Vipul Patel、Annie Penfornis、Olivier Pineau、Danig Pohin、Florent Potvain、Géraldine Poulain、Cécile Bertho Ruault、Michael Saunders、Jérôme Toum、H. Eric Xu、Robert X. Xu、Pascal M. Pianetti

  DOI：10.1021/jm058056x

  日期：2007.2.1

  The peroxisome proliferator activated receptors PPAR alpha, PPAR gamma, and PPAR delta are ligand-activated transcription factors that play a key role in lipid homeostasis. The fibrates raise circulating levels of high-density lipoprotein cholesterol and lower levels of triglycerides in part through their activity as PPAR alpha agonists; however, the low potency and restricted selectivity of the fibrates may limit their efficacy, and it would be desirable to develop more potent and selective PPAR alpha agonists. Modification of the selective PPAR delta agonist 1 (GW501516) so as to incorporate the 2-aryl-2-methylpropionic acid group of the fibrates led to a marked shift in potency and selectivity toward PPAR alpha agonism. Optimization of the series gave 25a, which shows EC50 = 4 nM on PPAR alpha and at least 500-fold selectivity versus PPAR delta and PPAR gamma. Compound 25a (GW590735) has been progressed to clinical trials for the treatment of diseases of lipid imbalance.
• 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
  申请人：TEIJIN LIMITED

  公开号：EP0513379B1

  公开（公告）日：1996-09-11
• US5614520A
  申请人：——

  公开号：US5614520A

  公开（公告）日：1997-03-25